Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Zealand Pharma: Clinical Trials & FDA Approval Profile

Zealand Pharma (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 2 active protocols (1 recruiting now), 13 completed protocols, and 1 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)44 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Zealand Pharma
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)2 (1)
Completed vs Stopped Early13 / 1 (6.3%)
Median Closed Actual Enrollment44 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals1 (1 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Zealand Pharma
Hospital Research SiteLocationShared Protocols
Vanderbilt University Medical CenterNashville, TN5
Universitätsklinikum BonnBonn, Bonn5
Charité Universitätsmedizin BerlinBerlin5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Zealand Pharma
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07197944Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Zealand Pharma Interactive Dossier, benchmark peers in Gastroenterology, Hepatology, and Renal, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI